List view / Grid view



Why biosimilars are changing the pharmaceutical industry

26 May 2017 | By Ho-ung Kim, Head of Strategy and Operations Division for Celltrion Healthcare

We caught up with Celltrion Healthcare's Ho-ung Kim to find out how biosimilars cut costs, increase access to medicine and are ultimately changing the industry…

Treating multiple myeloma: An interview with Janssen

17 May 2017 | By Dr Catherine Taylor, Haematology Therapeutic Area Lead, Janssen EMEA

We caught up with Janssen's Dr Catherine Taylor to talk monoclonal antibodies, the rise of immuno-oncology and treating multiple myeloma...

Pharmaceutical QbD: Omnipresence in the product development lifecycle

18 April 2017 | By , ,

The concept of Quality by Design (QbD) was implemented by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and United States Food and Drug Administration (FDA) around a decade ago, with the aim of adopting systematic approaches for developing high-quality pharmaceutical products for patients’…

FMD and supply chain security

18 April 2017 | By

Over 12 months ago, the European Union delegated regulation that supplements the Falsified Medicines Directive (FMD) was published in the Official Journal of the European Union, starting the countdown to the deadline of 9 February 2019, when most EU member-states, and three non-members currently, are expected to have implemented all…

Send this to a friend